Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term OutcomeFederico Lussana, Alessandro Rambaldi, Tamara Intermesoli et al.|Transplantation and Cellular Therapy|2016Cited by 88
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemiaRenato Bassan, Alessandro Rambaldi, Orietta Spinelli et al.|Blood Cancer Journal|2014Cited by 63
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07Renato Bassan, Alessandro Rambaldi, Chiara Pavoni et al.|Blood Cancer Journal|2020Cited by 45
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaRenato Bassan, Alessandro Rambaldi, Arianna Masciulli et al.|Haematologica|2015Cited by 32
Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)Renato Bassan, Alessandro Rambaldi, Arianna Masciulli et al.|Blood|2016Cited by 22